Procalcitonin and Pneumonia: Is it a useful marker?

被引：15

作者：

Christ-Crain M. ^{[1
]}

Müller B. ^{[1
]}

机构：

[1] University Hospitals, CH-4031 Basel

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 3期

关键词：

Procalcitonin; Lower Respiratory Tract Infection; Respir Crit; Pneumonia Severity Index; Antibiotic Stewardship;

D O I：

10.1007/s11908-007-0037-9

中图分类号：

学科分类号：

摘要：

An ideal biomarker for pneumonia should allow an early diagnosis and differential diagnosis from noninfectious conditions and should inform about the course and prognosis of the disease. Procalcitonin (PCT) covers these features better as compared to more commonly used biomarkers like Greactive protein or leukocyte count. PCT complements and improves the assessment of pneumonia based on careful patient history, dedicated physical examination, and appropriate cultures. Importantly, a PCT-based therapeutic strategy can safely and markedly reduce antibiotic courses in community-acquired pneumonia. However, as is the cast with all diagnostic surrogate markers, PCT can be increased in noninfectious conditions and may remain low in bacterial infections, especially localized infections. This stresses the importance of follow-up measurements, because PCT levels in these patients often show a gradual increase during follow-up. Although PCT is better than more common biomarkers for the prognosis of pneumonia and to predict survival and outcome, novel biomarkers show an even better prognostic accuracy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：233 / 240

页数：7

共 60 条

[1]

Becker K.L., Nylen E.S., White J.C., Et al., Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors, J Clin Endocrinol Metab, 89, pp. 1512-1525, (2004)

[2]

Weglohner W., Struck J., Fischer-Schulz C., Et al., Isolation and characterization of serum procalcitonin from patients with sepsis, Peptides, 22, pp. 2099-2103, (2001)

[3]

Zaidi M., Moonga B.S., Abe E., Calcitonin and bone formation: A knockout full of surprises, J Clin Invest, 110, pp. 1769-1771, (2002)

[4]

Hoff A.O., Catala-Lehnen P., Thomas P.M., Et al., Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene, J Clin Invest, 110, pp. 1849-1857, (2002)

[5]

Hirsch P.F., Baruch H., Is calcitonin an important physiological substance?, Endocrine, 21, pp. 201-208, (2003)

[6]

Nylen E.S., O'Neill W., Jordan M.H., Et al., Serum procalcitonin as an index of inhalation injury in burns, Horm Metab Res, 24, pp. 439-443, (1992)

[7]

Whang K.T., Steinwald P.M., White J.C., Et al., Serum calcitonin precursors in sepsis and systemic inflammation, J Clin Endocrinol Metab, 83, pp. 3296-3301, (1998)

[8]

Assicot M., Gendrel D., Carsin H., Et al., High serum procalcitonin concentrations in patients with sepsis and infection, Lancet, 341, pp. 515-518, (1993)

[9]

Muller B., Becker K.L., Schachinger H., Et al., Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit, Crit Care Med, 28, pp. 977-983, (2000)

[10]

Becker K.L., Muller B., Nylen E.S., Et al., Calcitonin gene family of peptides, Principles and Practice of Endocrinology and Metabolism, pp. 520-531, (2001)

← 1 2 3 4 5 6 →